Sleep Improvement Research Peptides
Overview
7 research peptides demonstrate sleep improvement properties. This collection covers their mechanisms, evidence base, and research applications.
Ipamorelin
Preclinical | Growth Hormone Secretagogue
Ipamorelin is the most selective growth hormone secretagogue (GHS) available, a synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5) that stimulates pulsatile GH release from the pituitary gland without significantly affecting cortisol,...
Mechanism: Ipamorelin (sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2) selectively binds to the Growth Hormone Secretagogue Receptor (GHS-R1a) on anterior pituitary somatotroph cells, increasing cAMP and activating...
CJC-1295
Preclinical | Growth Hormone Secretagogue
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.
Mechanism: CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous...
Sermorelin
Phase I–II Clinical Trials | Growth Hormone Secretagogue
Sermorelin is a synthetic 29-amino-acid peptide (MW ~3357.9 g/mol) corresponding to the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH).
Mechanism: Sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating both transcription of the HGH gene and pulsatile release of endogenous growth hormone.
GHRP-2
Phase I–II Clinical Trials | Growth Hormone Secretagogue
GHRP-2 (pralmorelin) is a synthetic hexapeptide growth hormone secretagogue (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, MW ~817.97 g/mol) that stimulates potent, dose-dependent GH release via the ghrelin receptor (GHS-R).
Mechanism: GHRP-2 (C45H55N9O6) binds to and activates ghrelin (GH secretagogue) receptors on pituitary somatotrophs, triggering robust pulsatile GH release.
Epithalon
Preclinical | Anti-Aging / Telomere
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly, MW ~390 g/mol) developed by Russian gerontologist Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
Mechanism: Epithalon (C14H22N4O9, MW ~390 daltons) activates telomerase, particularly the catalytic subunit TERT (telomerase reverse transcriptase), extending telomeres at chromosome ends.
DSIP
Preclinical | Sleep / Neuropeptide
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, C35H48N10O15) first isolated from rabbit brain in 1977 by Schoenenberger and Monnier.
Mechanism: DSIP (C35H48N10O15) modulates the central nervous system through interactions with GABA and NMDA receptors, reducing excitatory neuronal activity to facilitate onset and maintenance of deep sleep.
MK-677
Phase I–II Clinical Trials | Growth Hormone Secretagogue
MK-677 (Ibutamoren) is a potent, long-acting, orally-active, non-peptide ghrelin receptor (GHS-R1a) agonist that stimulates growth hormone release without injections.
Mechanism: MK-677 binds to the ghrelin receptor (GHS-R1a) in the pituitary gland and hypothalamus, mimicking the hunger hormone ghrelin.
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Synergistic Growth Hormone Effects of Sermorelin and Ipamorelin Blend
Research peptides Sermorelin and Ipamorelin may work together to boost growth hormone release from pituitary cells through distinct pathways. Sermorelin mimics the active part of natural GHRH, while Ipamorelin targets GHS-R1a receptors selectively. Laboratory studies indicate this combination could produce higher hGH peaks than either alone, with potential anabolic benefits via IGF-1.